Pipeline

May 7, 2018

Company	Drug/Device	Medical Condition	Status
Ocular Therapeutix	OTX-TIC (travoprost intracameral implant)	glaucoma and ocular hypertension	Phase I trial initiated
Galapagos NV and MorphoSys AG	MOR106	moderate-to-severe atopic dermatitis (AD)	Phase II trial initiated evaluating 180 subjects
ThromboGenics NV	THR-317 administered in combination with ranibizumab (Lucentis, Novartis)	Diabetic Macular Edema (DME)	Phase II trial initiated enrolling 70 subjects
Wize Pharma, Inc.	LO2A	Symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome	Phase IV trial initiated enrolling 60 subjects in the Israel
Immusoft Corporation	Immune System Programming	MPS I (Mucopolysaccharidosis type I)	Orphan Drug Designation granted by the FDA
Stealth Biotherapeutics	elamipretide	Leber’s hereditary optic neuropathy (LHON)	Orphan Drug Designation granted by the FDA
Conavi TM Medical Inc.	Novasight Hybrid System	simultaneous imaging of coronary arteries with both intravascular ultrasound (VUS) and Optical Coherence Tomography (OCT)	510(k) clearance granted by the FDA
Jazz Pharmaceuticals	Xyrem (sodium oxybate) oral solution	cataplexy and Excessive Daytime Sleepiness (EDS) in pediatric narcolepsy patients	sNDA filed with the FDA
Acceleron Pharma Inc.	ACE-083	Facioscapulohumeral muscular dystrophy (FSHD) treatment	Fast Track Designation granted by the FDA
SCYNEXIS, Inc.	Oral SCY-078	vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC	Fast Track Designation and Qualified Infectious Disease Product (QIDP) granted by the FDA